联影医疗发布上半年业绩，归母净利润9.98亿元，增长5.03%

Core Viewpoint - 联影医疗 reported a solid revenue growth of 12.79% year-on-year, reaching 6.016 billion RMB in the first half of 2025, driven by both domestic and international market performance [1] Financial Performance - The company's net profit attributable to shareholders was 999.8 million RMB, reflecting a year-on-year increase of 5.03% [1] - The net profit excluding non-recurring gains and losses was 966 million RMB, showing a significant growth of 21.01% year-on-year [1] - Basic earnings per share stood at 1.21 RMB [1] - A cash dividend of 1.3 RMB (including tax) per 10 shares is proposed for all shareholders [1] Business Growth - Domestic revenue growth was stable, supported by the acceleration of industry policy implementation and the company's product advantages and market competitiveness [1] - Internationally, the company achieved a remarkable revenue increase of 22.48% year-on-year, reaching 1.142 billion RMB, which now accounts for 18.99% of total revenue [1] - The overseas business has become a crucial driver for the company's sustained growth [1]